28 Apr 2021
Manufacturers of animal drug compounding products are expected to witness steady growth in demand over the coming years, with rise in requirement for oral, injectable, and topical routes of administration across regions. Demand for anti-infectives will rise the fastest, giving a boost to market expansion.
As stated in a new report by Fact.MR, North America and Europe will emerge as leading regional markets for animal drug compounding, while Asia Pacific will exhibit the fastest growth throughout the forecast period of 2021 to 2031. The global animal drug compounding market is projected to progress at a moderate CAGR over the next ten years.
Drug compounding products are highly required for companion animals such as dogs, cats, and others. With increase in inclination towards domestication of such animals, suppliers of animal drug compounding products are experiencing surge in demand around the globe.
According to a report titled “U.S. Pet Ownership Statistics”, published by the American Veterinary Medical Association, the percentage of households owning dogs in the United States is 38.4, while 25.4% of U.S. people have cats as their pets. This gives a glimpse of the rising demand for various animal drug compounding products around the globe, such as GI drugs, CNS agents, and others.
The global animal drug compounding market is highly competitive in nature. In order to sustain its leading positions, key players in this field are bringing in a wider variety of quality products.
For instance,
In its latest report, Fact.MR offers an unbiased analysis of the animal drug compounding market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product (anti-infectives (metronidazole, ketoconazole, and other antibiotics), anti-inflammatory (prednisolone, tramadol, and other anti-inflammatory), CNS agents (potassium bromide, gabapentin, and other CNS agents), GI drugs (apomorphine, ursodiol, cisapride, and other GI drugs), and others (methimazole and other drugs)), route of administration (oral, injectable, topical, rectal, and ocular), animal type (companion animals (dogs, cats, and others) and livestock animals), and dosage form (capsules, suspension, solutions, powders, and others), across seven major regions of the world (North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA).
Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support – encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.
For more information, refer to our market research report or contact the PR author.
Shambhu Nath Jha
Fact.MR
Sr. Consultant – Healthcare
E-mail: shambhu@factmr.com
Animal Drug Compounding Market
Free SampleAbout Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. We are known for our syndicated research, custom research, and consulting solutions.